Response to Lavin et al (2025)’s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
James, M. L., Pink, A. E., Woolf, R., Batty, P., Mahil, S., Smith, C. H., Whittaker, S. & Langan, S. M., 1 Sept 2025, In: Journal of Investigative Dermatology. 145, 9, p. 2325-2326 2 p.
Research output: Contribution to journal › Article › peer-review